Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II melphalan with autologous PBSC transplantation in castration‑resistant prostate cancer
2012-000351-14Phase 2Terminated
- Sponsor
- Barts Health NHS Trust
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of melphalan in prostate cancer (PCa), sponsored by Barts Health NHS Trust. Primary endpoint: Progression-free survival. Started Sep 2012; status: terminated.
02
Drugs
melphalan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2012-000351-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000351-14.